| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ... The Lancet 387 (10027), 1540-1550, 2016 | 6957 | 2016 |
| The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... Journal of Thoracic Oncology 11 (1), 39-51, 2016 | 4362 | 2016 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4112 | 2013 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3694 | 2014 |
| Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 … B Zhou, RM Carrillo-Larco, G Danaei, LM Riley, CJ Paciorek, GA Stevens, ... The Lancet 398 (10304), 957-980, 2021 | 2627 | 2021 |
| Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ... New England Journal of Medicine 377 (9), 829-838, 2017 | 2467 | 2017 |
| AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer PA Jänne, JCH Yang, DW Kim, D Planchard, Y Ohe, SS Ramalingam, ... New England Journal of Medicine 372 (18), 1689-1699, 2015 | 2341 | 2015 |
| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial WTA Van Der Graaf, JY Blay, SP Chawla, DW Kim, B Bui-Nguyen, ... The Lancet 379 (9829), 1879-1886, 2012 | 2289 | 2012 |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer DAE Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... Cancer discovery 4 (9), 1046-1061, 2014 | 2214 | 2014 |
| Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... New England Journal of Medicine 370 (13), 1189-1197, 2014 | 1859 | 2014 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1556 | 2012 |
| Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled … K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ... The Lancet Oncology 17 (5), 577-589, 2016 | 1317 | 2016 |
| Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ... Journal of clinical oncology 23 (11), 2493-2501, 2005 | 995 | 2005 |
| Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies TY Kim, DW Kim, JY Chung, SG Shin, SC Kim, DS Heo, NK Kim, YJ Bang Clinical cancer research 10 (11), 3708-3716, 2004 | 985 | 2004 |
| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 944 | 2018 |
| First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer AT Shaw, TM Bauer, F de Marinis, E Felip, Y Goto, G Liu, J Mazieres, ... New England Journal of Medicine 383 (21), 2018-2029, 2020 | 882 | 2020 |
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study SHI Ou, JS Ahn, L De Petris, R Govindan, JCH Yang, B Hughes, H Lena, ... Journal of clinical oncology 34 (7), 661-668, 2016 | 731 | 2016 |
| Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity P Ballard, JWT Yates, Z Yang, DW Kim, JCH Yang, M Cantarini, K Pickup, ... Clinical Cancer Research 22 (20), 5130-5140, 2016 | 693 | 2016 |
| Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients JC Lee, KM Lee, DW Kim, DS Heo The Journal of Immunology 172 (12), 7335-7340, 2004 | 681 | 2004 |
| Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial DW Kim, M Tiseo, MJ Ahn, KL Reckamp, KH Hansen, SW Kim, RM Huber, ... Journal of Clinical Oncology 35 (22), 2490-2498, 2017 | 641 | 2017 |
